房颤/房扑患者新冠疫苗接种后血栓栓塞风险:自控病例系列研究
结果显示总体风险未显著增加(IRR 0.93,95%CI 0.77-1.12),但未接受抗凝治疗的患者接种后风险显著升高(IRR 1.88,95%CI 1.39-2.54)。
要点
- 房颤/房扑患者接种新冠疫苗后21天内血栓栓塞风险总体未增加。
- 未接受抗凝治疗者接种后血栓栓塞风险显著升高(IRR 1.88)。
- 性别、年龄和疫苗类型均未见显著风险差异。
核心结论
- 房颤/房扑患者接种新冠疫苗总体不增加血栓栓塞事件风险,但未接受口服抗凝治疗者接种后风险升高,需个体化评估。
主要发现
- 接种后21天内血栓栓塞事件发生率比(IRR)为0.93(95%CI 0.77-1.12),与未暴露对照期相比无显著差异。
- 未接受抗凝治疗的患者接种后IRR为1.88(95%CI 1.39-2.54)。
- 性别、年龄或疫苗类型均未见显著风险差异。
关键数值与推荐
- 主要结局为缺血性卒中、短暂性脑缺血发作和系统性血栓栓塞的复合终点。
- 风险期定义为新冠疫苗接种后0-21天。
临床怎么用
- 对房颤/房扑患者接种新冠疫苗前应评估抗凝状态,未接受口服抗凝治疗者需谨慎权衡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. METHODS: This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0-21 days following COVID-19 vaccination. RESULTS: The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77-1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39-2.54) following vaccination. CONCLUSIONS: In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination.
引用
- Choi, Lim, Bea, et al. Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study. Eur Heart J. 2024. PMID: 38993069. doi:10.1093/eurheartj/ehae335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。